Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €34.68 EUR
Change Today +0.60 / 1.76%
Volume 346.6K
SAZ On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 3:35 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag (SAZ) Snapshot

Open
€34.09
Previous Close
€34.08
Day High
€34.90
Day Low
€34.06
52 Week High
07/29/15 - €34.90
52 Week Low
12/17/14 - €24.10
Market Cap
2.2B
Average Volume 10 Days
282.9K
EPS TTM
€0.88
Shares Outstanding
62.3M
EX-Date
06/4/15
P/E TM
39.4x
Dividend
€0.66
Dividend Yield
1.90%
Current Stock Chart for STADA ARZNEIMITTEL AG (SAZ)

Related News

No related news articles were found.

stada arzneimittel ag (SAZ) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel ag (SAZ) Details

STADA Arzneimittel AG engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s principal products include Omeprazole, a stomach medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Atorvastatin, an antilipemic; and Phospholipide, a liver medicine. The Branded Products segment offers non-prescription products. This segment primarily provides APO-go, a Parkinson medicine; Aqualor, a cold medicine based on seawater; Grippostad, a cold medicine; Snup, a nasal preparation; and Ladival, a sunscreen product. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany.

10,422 Employees
Last Reported Date: 05/8/15
Founded in 1895

stada arzneimittel ag (SAZ) Top Compensated Officers

Chairman of The Executive Board
Total Annual Compensation: €2.8M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.1M
Chief Business Development & Central Services...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2014.

stada arzneimittel ag (SAZ) Key Developments

STADA Group Presents at 2015 Russian Pharmaceutical Forum, May-20-2015 12:05 PM

STADA Group Presents at 2015 Russian Pharmaceutical Forum, May-20-2015 12:05 PM. Venue: Corinthia Hotel, Saint Petersburg, Russia. Speakers: Christoph Dengler, Vice President Legal.

Stada-Arzneimittel AG Reports Group Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Stada-Arzneimittel AG reported group earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported group sales of EUR 486.2 million against EUR 507.4 million a year ago. EBITDA was EUR 79.2 million against EUR 97.7 million a year ago. EBITDA, adjusted was EUR 92.6 million against EUR 114.7 million a year ago. Net income was EUR 21.2 million or EUR 0.35 per share against EUR 35.0 million or EUR 0.35 per share a year ago. Net income, adjusted was EUR 37.9 million or EUR 0.62 per share against EUR 52.6 million or EUR 0.87 per share a year ago. Operating profit decreased by 20% to EUR 50.4 million against EUR 63.1 million a year ago. For the year 2015, the board expected to be able to achieve slight overall growth in Group sales adjusted for currency and portfolio effects. The board expects a substantial decrease in adjusted EBITDA and adjusted net income. The board expects the ratio of net debt, excluding further acquisitions, to adjusted EBITDA to be at a level of nearly 3 in 2015.

Stada-Arzneimittel AG, Q1 2015 Earnings Call, May 07, 2015

Stada-Arzneimittel AG, Q1 2015 Earnings Call, May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAZ:GR €34.68 EUR +0.60

SAZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 3,756 INR +43.65
Hospira Inc $89.42 USD +0.19
Merck KGaA €94.42 EUR +1.90
Medicines Co/The $30.95 USD -2.53
UCB SA €66.84 EUR -0.16
View Industry Companies
 

Industry Analysis

SAZ

Industry Average

Valuation SAZ Industry Range
Price/Earnings 42.4x
Price/Sales 1.0x
Price/Book 2.2x
Price/Cash Flow 43.2x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit www.stada.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.